Tardive dyskinesia (TD) is a chronic, often persistent movement disorder associated with long-term use of dopamine receptor-blocking agents, especially antipsychotics used for schizophrenia, bipolar disorder, and other psychiatric conditions. Symptoms commonly include involuntary facial, mouth, tongue, trunk, or limb movements that can interfere with eating, speaking, walking, daily function, and quality of life. Risk is higher with long-term or high-dose dopamine receptor-blocking agent (DRBA) exposure, older age, female sex, Black race, mood disorders, cognitive disturbance, diabetes, substance use, HIV-positive status, and early extrapyramidal symptoms. Diagnosis relies on medication history, characteristic abnormal movements, exclusion of other movement disorders, and use of validated tools such as the Abnormal Involuntary Movement Scale.

Management begins with prevention, routine monitoring, and use of DRBAs at the lowest effective dose for the shortest necessary duration. When feasible, clinicians may consider gradual dose reduction, discontinuation, or switching to a lower-risk antipsychotic, though stopping antipsychotic therapy is often not practical because psychiatric symptoms may worsen. For moderate-to-severe or disabling TD, VMAT2 inhibitors are first-line pharmacologic therapy; valbenazine and deutetrabenazine are the only FDA-approved treatments. Both have shown significant reductions in TD severity versus placebo, with differences in dosing, formulation, metabolism, hepatic considerations, interactions, and adverse event profiles guiding individualized selection. The review emphasizes proactive screening, multidisciplinary management, and continued research into long-term safety, biomarkers, and nonpharmacologic options for refractory TD.

Reference: Sarna K. Managing tardive dyskinesia: drug-induced risks and therapeutic advances. Pharmacy Practice News. Published Jan 9, 2026. Accessed June 9, 2026. https://www.pharmacypracticenews.com/Clinical/Article/01-26/Tardive-Dyskinesia-Management-Risks-and-Therapeutic-Advances/79341.

This targeted narrative review examines the psychosocial, functional, and quality-of-life impact of tardive dyskinesia (TD), emphasizing that TD affects far more than visible abnormal movements. Across retrospective and prospective studies, patient and caregiver surveys, social media analyses, provider surveys, and consensus panels, TD was associated with impaired health-related quality of life, social withdrawal, stigma, embarrassment, reduced daily functioning, emotional distress, and work or activity impairment. Importantly, clinician-rated movement severity did not always align with patient-perceived impact, meaning even “mild” TD movements may cause substantial distress, avoidance, or functional limitation depending on the patient’s lived experience.

The review highlights the need to assess TD impact routinely, not just movement frequency or amplitude. Patients reported physical effects such as difficulty eating, speaking, swallowing, walking, and using their hands, along with psychological and social effects such as self-consciousness, fear of judgment, isolation, and reduced adherence to psychiatric medications. Caregivers also reported significant burden, including impaired daily activities, emotional strain, and work disruption. The article discusses tools that may help clinicians capture this impact, including AIMS impact items, the Clinician’s Tardive Inventory, Impact-TD, and the patient-reported Tardive Dyskinesia Impact Scale. The central takeaway is that TD treatment decisions should consider the patient’s functional and psychosocial experience, not movement severity alone.

Reference: Citrome L. Living with tardive dyskinesia: understanding the patient experience. CNS Spectr. 2026;31(1). doi: 10.1017/S1092852926100856.

This study describes the development and validation of the Tardive Dyskinesia Impact Scale (TDIS), a patient-reported outcome measure designed to capture how tardive dyskinesia (TD) affects patients’ daily lives. While the Abnormal Involuntary Movement Scale (AIMS) remains the clinician-rated standard for assessing TD movement severity in clinical trials, it does not fully capture the physical, cognitive, emotional, and social burden of TD from the patient perspective. To address this gap, researchers developed the TDIS using qualitative interviews with patients and caregivers, along with data from phase 3 VMAT2 inhibitor trials.

Qualitative findings showed that patients and caregivers found the TDIS relevant, understandable, and reflective of key TD impacts. Quantitative analyses supported two main domains: physical impact and socioemotional impact. The TDIS also appeared to measure aspects of TD burden that are distinct from AIMS scores, with only low correlations between the two measures. In phase 3 trial data, TDIS scores improved over 48 weeks, suggesting the scale was responsive to treatment-related change. The authors conclude that the TDIS may provide a useful patient-centered tool for assessing the real-world impact of TD beyond clinician-rated movement severity.

Reference: Farber RH, Stull DE, Witherspoon B, et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. J Patient Rep Outcomes. 2024 Jan 4;8(1):2. doi: 10.1186/s41687-023-00679-4.

This retrospective claims analysis examined adults with tardive dyskinesia (TD) who had at least one long-term care (LTC) stay between 2017 and 2021. Among 2,294 included patients, most were older adults, with 64.6% aged 65 or older and 67.3% female. Most were covered by Medicare, and the majority had multiple LTC stays. Skilled nursing facilities and nursing homes were the most common LTC settings. Patients had a high comorbidity burden, including mood disorders, schizophrenia, sleep disorders, substance use disorders, urinary tract infections, dysphagia, and dementia.

Medication use and healthcare resource utilization were also substantial. More than half of patients used antidepressants, anticonvulsants, or antipsychotics, and nearly half were prescribed three or more central nervous system-active medications that may increase the risk of falls or cognitive impairment in older adults. Anticholinergic use was also common, despite concerns that these medications may worsen TD and contribute to adverse outcomes in older patients. Emergency department (ED) visits were frequent, with nearly half of patients having at least one ED visit within one year after their index LTC stay. The authors conclude that TD in LTC settings is associated with high clinical burden, polypharmacy, and frequent healthcare use, underscoring the need for more targeted research and care strategies for older adults in LTC.

Reference: Bron M, Aweh G, Jen E, Patel A. Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings. Neurol Ther. 2025 Oct;14(5):2217-2226. doi: 10.1007/s40120-025-00820-z. Epub 2025 Sep 4.

Authors of this review explain that tardive dyskinesia (TD) remains a common and potentially irreversible complication of dopamine receptor-blocking agents, including both first- and second-generation antipsychotics. Because TD can emerge months or years after treatment begins and may significantly affect daily functioning, the article emphasizes the importance of early detection and routine screening. Recommended strategies include regular clinical assessment at every visit, structured use of the Abnormal Involuntary Movement Scale (AIMS), and informal tools that capture the patient’s and caregiver’s perspective on how movements affect physical, social, psychological, and vocational functioning. The review notes that even “mild” TD can cause embarrassment, social withdrawal, difficulty eating or speaking, impaired daily activities, and caregiver burden, which is why movement severity alone may not fully reflect the disorder’s real-world impact.

The article also highlights how TD management has changed with the availability of FDA-approved VMAT2 inhibitors. These agents allow patients to continue needed psychiatric treatment while reducing TD symptoms, and both short- and long-term studies support their efficacy and tolerability. Long-term data suggest that many patients achieve meaningful and sustained reductions in abnormal movements, although symptoms often return toward baseline after treatment is stopped, indicating that ongoing therapy may be needed for some patients. Overall, the review argues for a holistic, patient-centered approach to TD that combines structured clinician ratings, patient-reported outcomes, caregiver input, and individualized treatment planning in order to improve detection, reduce burden, and optimize long-term outcomes.

Reference: Matthews D. From Assessment to Intervention: Evidence-Based Approaches in Tardive Dyskinesia. CNS Spectr. 2025;30(1):e25. doi: 10.1017/S1092852925000082.

This case report describes a 52-year-old woman with schizophrenia who developed tardive sensory syndrome (TSS) after approximately 3 months of treatment with lurasidone. Her symptoms were notable for mandibular sensory paresthesia and pain, without the more commonly recognized abnormal involuntary movements often associated with tardive syndromes, such as orofacial dyskinesia, tremor, rigidity, dystonia, or bradykinesia. The patient had previously been treated with several antipsychotics, but lurasidone had most recently been started after olanzapine was discontinued because of weight gain. To rule out other causes, clinicians conducted an extensive evaluation, including laboratory testing, brain CT imaging, and dental consultation, all of which were unrevealing. Based on the clinical features and exclusion of secondary causes, TSS was suspected, and her baseline Extrapyramidal Symptom Rating Scale (ESRS) score was 18 before her antipsychotic regimen was changed.

After lurasidone was discontinued and the patient was switched to quetiapine, her sensory symptoms improved markedly. Within 1 month, her ESRS score improved by 65%, falling from 18 to 6, and by 6 months her pain had fully resolved, with a visual analog pain score of 0/10. The authors suggest that this may be the first reported case of TSS associated with lurasidone and review several possible mechanisms, including dopamine receptor effects, serotonergic involvement, and oxidative stress-related injury. They also note that although second-generation antipsychotics are often viewed as carrying a lower risk of tardive syndromes, they are not risk-free. Overall, the report highlights the importance of recognizing painful sensory symptoms as a possible tardive phenomenon and considering medication changes promptly when these symptoms emerge.

Reference: Lin MC, Chang YY, Lee Y, Wang LJ. Tardive sensory syndrome related to lurasidone: A case report. World J Psychiatry. 2023 Mar 19;13(3):126-130. doi: 10.5498/wjp.v13.i3.126.

Authors of a narrative review examine the current European landscape of tardive dyskinesia (TD) and argue that TD remains both common and underrecognized across the region. Drawing on limited European data supplemented by findings from other regions, the authors note that TD prevalence remains clinically meaningful even in the era of second-generation antipsychotics, with prior estimates suggesting rates of 22.3% in Europe and a global mean prevalence of 25.3%. They emphasize that diagnosis is often missed or delayed because of poor recognition of the full range of TD symptoms, lack of systematic screening, inconsistent use of diagnostic criteria and rating scales, and shortcomings in coding systems. This includes the absence of a distinct TD code in some countries. The authors also highlight that accurate diagnosis is complicated by the need to distinguish TD from other abnormal movement disorders, and that better training for psychiatrists and closer collaboration with neurologists could help improve detection.

The authors further underscore the substantial disease burden and quality-of-life impact of TD. TD may persist even after stopping the causative agent, increase healthcare use and costs, worsen outcomes related to the underlying psychiatric illness, and negatively affect physical, psychological, social, and vocational functioning. From the European perspective, the authors argue that care is fragmented because TD-specific guidelines are sparse, inconsistent, or absent, and access to newer treatments varies widely by country. Although VMAT2 inhibitors have the strongest evidence base, their availability in Europe is uneven, which may contribute to undertreatment. Overall, the authors call for pan-European guidelines, improved access to newer therapies, better clinician and patient education, more routine screening, and clearer International Classification of Diseases coding. They also emphasize the need for more Europe-based research to better define TD prevalence, burden, and best practices for management.

Reference: Colosimo C, Jain R, Duma K, Kurzeja A, Arango C. A European perspective on tardive dyskinesia. Eur Neuropsychopharmacol. 2026 Mar;104:112740. doi: 10.1016/j.euroneuro.2025.11.017. Epub 2025 Dec 19.

Researchers of a recent retrospective claims-based study examined patients with tardive dyskinesia (TD) living in long-term care (LTC) settings and found that they were typically older, medically complex, and exposed to substantial polypharmacy. Of 2,294 eligible patients, nearly two-thirds were age 65 or older, more than two-thirds were female, and most were covered by Medicare. Repeated LTC stays were common, and most patients lived in skilled nursing facilities or nursing homes. The population had a high comorbidity burden, with mood disorders, schizophrenia, sleep disorders, substance abuse, urinary tract infections, dysphagia, and dementia all frequently reported. Medication use was also extensive, with high rates of antidepressants, anticonvulsants, antipsychotics, and anticholinergics. Nearly half of patients were taking at least three central nervous system-active medications that may increase the risk of falls or cognitive impairment.

Healthcare utilization was also high in this population. Nearly half of patients had at least one emergency department (ED) visit within a year after their index LTC stay. Almost two-thirds had an ED visit at some point during follow-up, with a median of four visits overall. The authors say these findings highlight the considerable clinical burden of TD in LTC residents. Furthermore, it raises concern about the frequent use of anticholinergics, which are not recommended for TD and may worsen symptoms or contribute to cognitive and physical harm in older adults. Overall, the study points to a need for better TD-focused care in LTC settings, including more tailored guidelines, improved medication management, and treatment approaches that account for the needs of older adults, including those with dysphagia and multiple comorbidities.

Reference: Bron M, Aweh G, Jen E, Patel A. Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings. Neurol Ther. 2025;14(5):2217-2226. doi: 10.1007/s40120-025-00820-z.

Despite a steady rise in brain-imaging research on tardive dyskinesia (TD) over recent decades, the overall evidence base remains limited and inconsistent. Authors of this review argue TD should not be viewed only as a motor syndrome. Studies link TD in schizophrenia to broader deficits—including cognitive deterioration—beyond abnormal movements. The authors propose that pairing cognitive assessment with structural and functional neuroimaging could improve how clinicians and researchers assess TD. This approach may also help anticipate cognitive change in affected patients.

To map what’s known, the authors conducted a narrative (non-systematic) review of English-language studies (1980–2022) identified across multiple databases using TD plus brain imaging search terms. They summarize how TD is measured in both animal and human research, with AIMS commonly used in people. They also outline imaging approaches used to study TD, along with neuromodulation work such as deep brain stimulation. Across studies, the most recurrent signals involve basal ganglia differences (including caudate/putamen/globus pallidus) and dopaminergic findings that vary by method. The review also notes possible roles for iron-related changes and MRI relaxation measures, alongside additional cortical/limbic and metabolic findings. Overall, the authors call for more rigorous, replicated, and diverse neuroimaging research. It emphasizes systematic methods and longitudinal designs to clarify TD brain mechanisms, cognitive correlates, and prediction of risk and severity.

Reference: Uludag K. Brain imaging studies on Tardive Dyskinesia in schizophrenia patients and animal models: a comprehensive review. Future Neurology. 2024 Dec 11;19(1):2433936. doi: 10.1080/14796708.2024.2433936.

Antipsychotic (neuroleptic) medications are widely used for chronic mental illnesses such as schizophrenia but can cause movement disorders, including tardive dyskinesia (TD). TD often presents as repetitive involuntary movements of the mouth and face. Because oxidative stress has been proposed as a contributor to TD, vitamin E has been studied as a potential adjunct to prevent TD from worsening or to reduce symptoms. This review evaluated the clinical effects of vitamin E in adults with schizophrenia or other chronic mental illness who developed antipsychotic-induced TD while remaining on antipsychotic therapy. It also examined whether effects persist over time or are stronger in early-onset TD (<5 years).

Across 13 small, poorly reported randomized trials (478 participants), vitamin E did not show clear benefit over placebo for clinically important improvement in TD symptoms (low-quality evidence). However, limited evidence suggested vitamin E might reduce the risk of symptom deterioration compared with placebo. The review found no reliable differences in adverse effects, extrapyramidal symptoms, or study dropouts. Patient-centered outcomes like quality of life and social functioning were not reported, and there were no trial data to assess vitamin E specifically in early-onset TD. Overall, the authors conclude vitamin E may help protect against TD worsening but does not appear to meaningfully improve established TD. They also call for larger, higher-quality trials to better define its role.

Reference: Soares-Weiser K, Maayan N, Bergman H. Vitamin E for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Jan 17;1(1):CD000209. doi: 10.1002/14651858.CD000209.pub3.

Antidepressant-induced movement disorders are uncommon adverse drug reactions, and the risk may vary by drug and antidepressant class. Authors of this study used reports from VigiBase (the World Health Organization global pharmacovigilance database) from January 1967 to February 2017 to evaluate whether movement disorders were reported disproportionately often with antidepressants. Using a case/non-case design, the authors calculated reporting odds ratios (RORs) for nine movement-disorder subtypes. They then adjusted those RORs for age, sex, co-reported drugs that can induce movement disorders, and drugs used to treat movement disorders.

Among 14,270,446 total reports, 1,027,405 (7.2%) involved at least one antidepressant, and 29,253 (2.8% of those) included a movement disorder. The cohort skewed female (female/male ratio 2.15) with a mean age of about 51 years. Antidepressants overall showed increased reporting for all movement-disorder subtypes, strongest for bruxism and weakest for tics. Most antidepressant classes also showed significant associations across subtypes, with restless legs syndrome showing a class-specific signal only for serotonin reuptake inhibitors. Several antidepressants appeared more strongly associated. Commonly implicated agents included citalopram, paroxetine, duloxetine, and mirtazapine, and additional signals were reported for multiple other antidepressants. The authors conclude these findings suggest potential harmful associations that warrant clinical vigilance and early monitoring. However, they emphasize the analysis is exploratory and should be refined by future epidemiologic studies.

Reference: Revet A, Montastruc F, Roussin A, et al. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry. 2020 Jun 16;20(1):308. doi: 10.1186/s12888-020-02711-z.

Authors of this analysis from the RE-KINECT study examined how “possible” tardive dyskinesia (TD) affects unpaid caregivers of adults with psychiatric disorders on antipsychotics. Of 739 patients screened, 204 had clinician-confirmed abnormal involuntary movements, and 41 qualified caregivers (mostly family/friends, about half employed) completed questionnaires. Caregivers rated movement severity and location, patients’ overall health, and time spent helping with different conditions. For patients who self-reported abnormal movements, caregiver ratings of severity correlated well with patient ratings and, more modestly, with clinician ratings—especially for head/face movements and number of affected regions—suggesting caregivers can offer clinically useful observations.

Caregivers reported that TD and mental health issues meaningfully affected their own lives, with many spending substantial time on mental health support, physical activity/nutrition, and movement symptoms. Among those who noticed movements, at least half said these movements had “some” or “a lot” of impact on their ability to do usual activities, work, self-care, and socializing. Many reported frustration, anger, or embarrassment. The authors conclude that TD adds significant, often overlooked burden for caregivers and that clinicians should routinely screen for TD, actively include caregiver input in assessments, and connect caregivers with education and support. They also emphasize the need for further research to clarify the long-term and financial effects of TD-related caregiving.

Reference: Cutler AJ, Caroff SN, Tanner CM, et al. Caregiver-Reported Burden in RE-KINECT: Data From a Prospective Real-World Tardive Dyskinesia Screening Study. J Am Psychiatr Nurses Assoc. 2023 Sep-Oct;29(5):389-399. doi: 10.1177/10783903211023565.

Tardive dyskinesia (TD) is a persistent movement disorder linked to long-term use of dopamine receptor–blocking medications, and older adults (≥60 years) are at particularly high risk. In long-term care (LTC) settings, TD can add to functional burden, worsening balance, swallowing, and daily functioning. This retrospective, longitudinal study used the STATinMED Real-World Insights Database (2017–2022) to assess how common TD is among LTC residents and to describe their demographics, comorbidities, treatment patterns, and healthcare utilization. Adults with a TD diagnosis, at least one LTC stay, and continuous claims data for 12 months before LTC admission and 12 months after LTC discharge were included.

Among 20,176 patients with TD, 2,294 met criteria for continuous benefits and were analyzed. Most were older (64.6% ≥65 years), female (67.3%), and covered by Medicare (76.8%), with a high comorbidity burden (mean Charlson Comorbidity Index 3.72). Mood disorders were common (66.1%), and antidepressants were the most frequently used medications (56.1%). Polypharmacy was notable: nearly half of patients were prescribed three or more central nervous system–active medications, heightening risk of falls and cognitive impairment in older adults. Post-LTC, 64.8% had at least one emergency department visit. Overall, the study highlights substantial medical complexity and polypharmacy among LTC residents with TD. Researchers underscore the need for further research and targeted interventions to improve outcomes such as fall-related injuries and decline in activities of daily living.

Reference: Bron M, Aweh G, Jen E, Patel A. Real-World Claims Analysis to Characterize the Burden of Tardive Dyskinesia in Long-Term Care Settings. Neurol Ther. 2025 Oct;14(5):2217-2226. doi: 10.1007/s40120-025-00820-z.

Withdrawal-emergent dyskinesia (WED) is a transient movement disorder that appears after rapid taper or abrupt discontinuation of antipsychotics. Unlike classic tardive dyskinesia (TD), WED usually improves within weeks. This case describes a 13-year-old with disruptive mood dysregulation disorder and attention-deficit hyperactivity disorder who developed reversible oral dyskinesia during inpatient care after ziprasidone was stopped and methylphenidate was up-titrated. Symptoms (facial grimacing, mouth twitching) emerged within a day of antipsychotic cessation, were managed with benztropine and brief ziprasidone, and ultimately resolved as stimulants were tapered and bupropion was started.

The authors suggest dopamine D2 receptor hypersensitivity from prior antipsychotic exposure, unmasked by rapid withdrawal and amplified by stimulant-driven dopaminergic tone, as a plausible mechanism. A serotonin-syndrome-like process was considered but not supported clinically. Key practice points: avoid abrupt antipsychotic discontinuation, consider slower tapers and cross-titration to lower-dopaminergic or non-stimulant agents, and recognize WED/pseudo-tardive presentations as distinct from persistent TD. Heightened clinician awareness is especially important in pediatric populations where antipsychotics and stimulants are commonly co-managed.

Reference: Haji Rahman R, Dharmapuri S. Oral Dyskinesia in a Pediatric Patient Following Concurrent Use of Neuroleptics and Stimulants: Treatment Strategy Considerations to Avert Avoidable Adverse Side Effects. Cureus. 2023;15(4):e38294. doi: 10.7759/cureus.38294.

Tardive dyskinesia (TD) arises after exposure to dopamine receptor–blocking agents and carries a broad burden across physical, psychological, social, and professional domains. Investigators of a Journal of Clinical Psychiatry (JCP) survey of 269 US patients highlighted substantial absenteeism and presenteeism and frequent medication changes due to TD. To improve assessment, investigators introduced the Clinician’s Tardive Inventory (CTI), a six-domain tool that rates symptom frequency and functional impact. Expert video reviews showed good to excellent reliability overall, with some challenges for subjective measures like “bother.”

Authors of another JCP analysis using Japan’s Adverse Drug Event Report database (2004-2021) compared long-acting injectable antipsychotics (LAIs) with oral equivalents. Signals suggested lower reported TD with LAI paliperidone vs oral paliperidone and generally lower reporting with LAI second-generation agents than first-generation options, though patterns varied by drug. The authors caution that database biases, limited treatment detail, and inability to determine true risk or severity limit firm conclusions. They also advise clinicians to monitor for TD during LAI therapy, noting that further research is needed to validate tools like the CTI and refine prevention and treatment strategies.

Reference: Storey D. Research Helps Demystify Tardive Dyskinesia. Psychiatrist.com. Published April 29, 2024. Accessed October 2, 2025. https://www.psychiatrist.com/news/research-helps-demystify-tardive-dyskinesia/

Tardive dyskinesia (TD) was first described after chlorpromazine use in the 1950s and soon broadened from oral–buccal–lingual (OBL) movements to a spectrum of dopamine receptor blocking agents (DRBA)-induced hyperkinetic disorders (eg, chorea, dystonia, akathisia, myoclonus, tics, tremor). Non-antipsychotic DRBAs like metoclopramide can also cause these conditions. Phenomenology overlaps with spontaneous disorders (eg, spontaneous oral dyskinesia), but TD typically shows wider presentations, occurs more often in exposed populations, and can arise after brief exposure—sometimes worsening on drug withdrawal and improving with dose increase. DSM-5/5-TR recognizes TD separately within broader tardive phenomena, yet terminology has remained inconsistent.

To resolve nomenclature, a three-round modified Delphi panel of movement-disorder neurologists and psychiatrists compared umbrella terms. Across rounds, most experts preferred “tardive syndrome” as the umbrella term for all DRBA-induced tardive conditions, reserving “tardive dyskinesia” for the classic OBL stereotypy (with or without chorea). The authors recommend adopting “tardive syndrome” universally for the umbrella category and maintaining TD for the specific subtype, to improve clarity across research, clinical communication, assessment, and care. They also noted that further work is needed to refine phenotypes, pathophysiology, and standardized tools.

Reference: Frei K, Scott A, Caroff SN, et al. Tardive dyskinesia versus tardive syndrome. What is in a name? Parkinsonism Relat Disord. 2025;133:107295. doi: 10.1016/j.parkreldis.2025.107295.

Tardive dyskinesia (TD) significantly impacts patients' physical, cognitive, and psychosocial functioning. The Abnormal Involuntary Movement Scale (AIMS) is commonly used to evaluate TD treatment efficacy in clinical trials but does not capture the patient perspective on the impacts of uncontrolled movements. The Tardive Dyskinesia Impact Scale (TDIS) was developed as a patient-reported outcome measure to address this gap. This study aimed to assess the psychometric properties of the TDIS to determine if it is suitable for measuring the impact of TD from a patient's perspective.

The qualitative results of the study indicated that the TDIS effectively captures the key impacts of TD as reported by patients and caregivers. Quantitative analysis revealed two underlying domains of the TDIS: physical and socioemotional. The TDIS demonstrated good construct validity, including responsiveness to treatment-related changes. The TDIS also showed a low correlation with the AIMS, indicating it provides unique information. Overall, the TDIS complements the AIMS and can be used to assess changes in TD impact over time, offering a more comprehensive evaluation of the disease’s effects.

Reference: Farber RH, Stull DE, Witherspoon B, et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. J Patient Rep Outcomes. 2024;8(1):2. doi: 10.1186/s41687-023-00679-4. 

The Tardive Dyskinesia Impact Scale (TDIS) is a patient-reported outcome tool designed to assess how tardive dyskinesia (TD) affects patients’ daily lives—including physical function, emotional well-being, and social interaction. Unlike the commonly used Abnormal Involuntary Movement Scale, which is clinician-reported and focused on the severity of observed movements, the TDIS captures the subjective experience of living with TD. Developed through extensive qualitative research with patients and caregivers, and refined based on feedback, the 11-item questionnaire asks patients to rate how uncontrollable movements impact speech, mobility, dexterity, pain, social encounters, and emotional health. Findings from two phase 3 clinical trials (KINECT3 and KINECT4) confirmed that the TDIS is reliable, valid, and responsive to changes in symptom burden over time.

Psychometric analyses revealed that the TDIS has two core domains—physical and socioemotional impacts—with strong internal consistency and test–retest reliability. The scale was able to detect symptom improvement during treatment and worsening during medication washout, indicating its usefulness as a monitoring tool in both clinical trials and real-world care. Importantly, TDIS scores had weak correlation with AIMS, highlighting that the two tools measure different aspects of TD and should be used together for a more complete picture. The TDIS fulfills FDA recommendations for incorporating the patient voice into clinical assessments and offers a practical, validated solution for tracking how TD affects quality of life from the patient’s point of view.

Reference: Farber RH, Stull DE, Witherspoon B, et al. The Tardive Dyskinesia Impact Scale (TDIS), a novel patient-reported outcome measure in tardive dyskinesia: development and psychometric validation. J Patient Rep Outcomes. 2024;8(1):2. doi: 10.1186/s41687-023-00679-4.

Tardive dyskinesia (TD) is a potentially irreversible movement disorder caused by antipsychotic medications, marked by involuntary, repetitive movements that can significantly impair quality of life. This study aimed to assess how TD-related movements influence others' perceptions in social and professional settings. Using a randomized, blinded digital survey, general population participants viewed videos of actors simulating either TD or no TD movements and then responded to questions related to employment, dating, and friendship. Separate assessments were conducted for mild-to-moderate and moderate-to-severe TD, with expert physicians confirming the authenticity and severity of the simulated movements using Abnormal Involuntary Movement Scale scores.

Researchers found that participants consistently responded more negatively to individuals displaying TD movements across all domains. Compared to control participants, those who viewed actors with TD movements were significantly less likely to consider them for employment, find them attractive, or express interest in friendship. This trend held true regardless of the severity of TD. The results suggest that visible TD symptoms may contribute to stigma, social isolation, and reduced life opportunities. As the first randomized study to quantify the social and professional consequences of TD, these findings highlight the need for increased awareness and strategies to address stigma in this population.

Reference: Ayyagari R, Goldschmidt D, Mu F, Caroff SN, Carroll B. An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia. Clin Psychopharmacol Neurosci. 2022;20(1):154-166. doi: 10.9758/cpn.2022.20.1.154.

Tardive dyskinesia (TD), a persistent involuntary movement disorder linked to long-term antipsychotic use, is often underreported or misdiagnosed in routine clinical practice. This retrospective study analyzed electronic health records (EHRs) from over 32,000 US adults with psychotic disorders who were prescribed antipsychotics between 1999 and 2021. Researchers identified patients with either abnormal movements suggestive of TD or documented TD through manual review of clinical notes. While 1,301 patients had clinical indicators of TD in unstructured EHR data, only 64 (4.9%) of them had a formal ICD-coded diagnosis—indicating a significant gap in diagnosis and documentation.

Findings suggest racial and clinical setting disparities in TD diagnosis. Black/African American patients were significantly less likely to receive an ICD-TD diagnosis compared to white patients. Patients treated at community mental health centers were more likely to receive a diagnosis than those treated at academic medical centers. These results underscore the need for improved recognition and documentation of TD in clinical settings to ensure timely intervention and equitable access to treatment. Better diagnostic practices could help identify patients who may benefit from newer therapeutic options for managing TD.

Reference: Griffiths K, Won Y, Lee Z, Wang L, Correll CU, Patel R. Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data. BMC Psychiatry. 2025;25(1):407. doi: 10.1186/s12888-025-06780-w.

This pilot study aimed to use social media listening (SML) to gain insights into the patient and caregiver experiences of tardive dyskinesia (TD), a movement disorder associated with prolonged use of dopamine receptor-blocking agents like antipsychotics. Social media platforms, blogs, and forums were analyzed for patient and caregiver posts between March 2017 and November 2019. A total of 261 posts were identified, with 107 used for analysis. The study found that 64% of the posts expressed negative sentiments, with patients often feeling angry about the medication causing their symptoms and insecure about societal acceptance.

The study also revealed that movement-related symptoms were the most common concern for patients, with emotional distress being a significant aspect of their experience. Patients described feelings of anger and insecurity, particularly related to the stigma of having symptoms from a medication used for another condition. The findings suggest that SML can be a valuable tool in understanding the unmet needs of patients with TD. Researchers stress that the emotional and social challenges associated with the condition are significant and should be considered when addressing TD in clinical settings.

Reference: Farrar M, Lundt L, Franey E, Yonan C. Patient perspective of tardive dyskinesia: results from a social media listening study. BMC Psychiatry. 2021;21(1):94. doi: 10.1186/s12888-021-03074-9. 

A recent study explored the prevalence and risk factors for tardive dyskinesia (TD) in patients with schizophrenia undergoing long-term antipsychotic treatment. It found that 35.9% of patients exhibited TD symptoms, with older age, Chinese ethnicity, and prolonged antipsychotic use being significant risk factors. The prevalence of TD in these patients highlights the importance of regular monitoring and early detection, particularly for older patients and those with extended histories of antipsychotic treatment. The study also noted that facial and oral movements were the most commonly impacted areas in TD, resulting in significant impairments in self-care and quality of life, as measured by the Personal and Social Performance Scale.

Additionally, the study revealed that patients with TD were more likely to experience severe impairments across various clinical scales, including the Clinical Global Impression, indicating a higher level of overall clinical severity. The findings suggest that tailored treatment strategies, including personalized monitoring based on factors like age, ethnicity, and treatment history, are crucial for mitigating the risk of TD. The study calls for continued vigilance in monitoring TD and further research into ethnic-specific risk factors and long-term management strategies for TD in patients with schizophrenia.

Reference: Nedunjelian A, Ng CG, Lim PK, Sulaiman AH, Koh OH, Francis B. The Prevalence of Tardive Dyskinesia In Patients With Schizophrenia Treated With Antipsychotics In Malaysia. Neuropsychiatr Dis Treat. 2025;21:465-475. doi: 10.2147/NDT.S494458. 

Emerging research suggests that immune system dysregulation may play a role in the development of tardive dyskinesia (TD), a movement disorder linked to long-term use of dopamine receptor-blocking antipsychotics. Rodent studies show increased levels of pro-inflammatory cytokines—such as IL-1β, IL-6, and TNF-α—in the striatum after chronic haloperidol use, often correlating with orofacial dyskinesia severity. However, human findings are inconsistent. Evidence points to neuroinflammation, particularly in the striosomal compartment of the striatum and lateral habenula, as a possible mechanism driving TD, especially its classic orofacial form.

This review proposes that TD may result not only from dopamine receptor sensitivity but also from neuroinflammatory processes involving both central and peripheral immune activation. Regions like the choroid plexus and epithalamus may influence nearby brain structures such as the dorsal diencephalic connection system, impacting motor regulation. Given the overlap between schizophrenia, antipsychotic treatment, and neuroimmune signaling, more research is needed to explore inflammation’s role in TD and identify potential therapeutic targets.

Reference: Loonen AJM. Putative role of immune reactions in the mechanism of tardive dyskinesia. Brain Behav Immun Health. 2023;33:100687. doi: 10.1016/j.bbih.2023.100687. 

The pathophysiology of tardive dyskinesia (TD) involves prolonged dopamine receptor blockade, leading to receptor supersensitivity and oxidative damage in the striatum. This case report discusses a 62-year-old male patient presenting with involuntary tongue movements and a history of long-term antidepressant and mood stabilizer use. The patient exhibited moderate spontaneous tongue movements and mild distress, as assessed using the Abnormal Involuntary Movement Scale. Management included altering his medication regimen by switching to clonazepam and clozapine, performing coronoplasty to prevent trauma from tongue movements, and providing counseling to improve his psychosocial well-being. These measures significantly reduced the severity of his symptoms.

Preventive strategies include altering antipsychotic regimens, reducing dosages, and considering second-generation antipsychotics or vesicular monoamine transporter 2 inhibitors. The case underscores the importance of early diagnosis and comprehensive management, including collaboration between oral physicians and psychiatrists, to mitigate the functional and psychosocial impact of TD, particularly in geriatric patients.

Reference: Ruparelia P, Pandya U, Gill N, Verma O. Restless tongue: Lingual Tardive Dyskinesia - A rare case report. J Oral Biol Craniofac Res. 2022;12(1):99-101. doi: 10.1016/j.jobcr.2021.10.006.